Geographic atrophy is an eye condition that can severely impact a person’s vision, which can affect their routine and independence. Once a person develops geographic atrophy, it cannot be reversed and ...

IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed ...

NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...

*Intended for U.S. Audiences only. Whether it was a weekend getaway to Chicago to see a play or snapping pics of Big Ben in London, going on adventures was always a highlight for Jan,* a 56 year-old ...

In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month ...

Please provide your email address to receive an email when new articles are posted on . Izervay injections for geographic atrophy led to acute IOP increases in 3% of eyes in a real-world dataset ...

"Geographic atrophy is a progressive disease that can lead to irreversible vision loss and early treatment can have a significant impact on patients' lives. Receiving a permanent J-code in the U.S.